Promedix is a medical device startup which is developing noninvasive, fingertip patient monitors to improve recognition of circulatory dysfunction. Its devices help in the diagnostic evaluation and monitoring of therapeutic interventions for multiple medical conditions including trauma, dehydration, and sepsis. The company was founded in 2019 and is headquartered in Portland, Oregon.
PneumoNIX Medical is focused on creating gel-based technologies aimed at preventing complications related to percutaneous procedures, particularly in the context of soft tissue biopsies. The company's innovative medical devices are designed to minimize the risk of collapsed lung complications that may occur during CT-guided lung biopsies. By addressing these critical issues, PneumoNIX Medical seeks to enhance patient safety and improve outcomes in medical interventions that involve needle insertions.
CoraVie Medical is a medical device startup in its early stages that is changing the way blood pressure is monitored for millions of patients who have uncontrolled hypertension and are at high risk of an adverse event such as kidney failure, stroke, or heart failure. CoraVie Medical's gadget will be the first to deliver early actionable insights to enable cost-effective therapies, drive behaviors, and assist in maintaining appropriate blood pressure levels.
Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.
BioSuperior is a preclinical stage biotherapeutics company developing cost-effective, non-invasive, and easily accessible technologies to cure lung disease and repair damaged lung tissue. They have bio-engineered a novel synthetic pulmonary surfactant prototype, BioSurf, an essential biomaterial required for breathing and having direct therapeutic effects that will be used to deliver potent drugs that restore normal lung function.
We are a mission-driven company dedicated to providing next-generation medical optical imaging to clinics. With our technology, conditions can be viewed, interpreted, and treated directly at primary care - with greater accuracy and months earlier than ever before. Our hardware platform and world-class AI/ML software enable practitioners anywhere to work remotely with specialists to safely and quickly visualize areas of concern.
Evolution Devices is building technology to assist and enhance movement. Their flagship product, EvoWalk, is an FDA-Cleared bio-electronic wearable device that helps people living with mobility impairments due to neurological conditions.
COPD will cost $61 billion per year by 2029, but no technologies can evaluate lung function from home, leaving patients and doctors to rely on questionnaires. Samay will disrupt the remote diagnostic market just as Dexcom did with Diabetes and iRhythm with cardiac arrhythmias. Our chest patches use a patented technology that diagnoses COPD with 90% accuracy and detects exacerbation biomarkers with 83% accuracy, passively. We're building an AI-assisted management and diagnostic platform to accompany patients and doctors throughout the care continuum, from exacerbation detection to determining effective therapies for more personalized care, all from home.
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.
Aqua Science offers a global platform of technologies and fast and reliable solutions for the testing and treatment of water. They provide research and development, custom reagent and kit manufacture, product assembly, lyophilization services, and contract manufacturing services.
Birch Biosciences focuses on developing a proprietary platform that engineers enzymes for an innovative and sustainable plastic recycling process. By utilizing artificial intelligence, bioinformatics, and high-throughput screening techniques, the company creates enzymes that naturally and efficiently break down plastics. This method stands out from traditional recycling by producing virgin-quality, environmentally sustainable, and cost-competitive recycled materials, thereby contributing to a circular plastics economy. Birch Biosciences aims to provide businesses with an effective solution for addressing plastic waste while ensuring economic viability.
Canomiks operates a genomics and artificial intelligence-based technology platform that focuses on testing and certifying the biological efficacy and safety of ingredients and formulations. Its services cater to the functional food and beverage, dietary supplement, and skincare industries, allowing companies to develop safe and effective products efficiently. By leveraging omics science, data analytics, machine learning, and bioinformatics, Canomiks streamlines the validation process for product efficacy, ultimately enabling clients to enhance product quality while reducing development time and costs. The company's long-term vision is to actualize the concept of food as medicine.
PureBiomass provides reliable, sustainable, and robust algae cultivation system services. They also provide waste water remediation, live feeds for shellfish, omega-3 production, and sustainable fish production services.
UCHU Biosensors develops a platform of tooth mounted sensors to effortlessly track health through saliva.
Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.
GeniPhys is a medical technology company that plans to develop and commercialize its patented technology. The company was founded in 2014 and is based in Zionsville, Indiana.
Intelligent Medicine specializes in software and simulation services focused on enhancing safety in medical environments through innovative technologies. The company has developed a simulation platform that enables architects and facility stakeholders to evaluate and optimize building designs and operational protocols. By testing various designs and protocols, the platform helps to identify areas for improvement, thereby reducing the likelihood of infectious disease transmission and alleviating user congestion. This capability allows for a rapid feedback loop, supporting the planning and implementation of effective safety policies and design strategies to improve overall outcomes in healthcare settings.
Auctus Biologics is a pre-clinical biotechnology company that develops antibody mimetics for therapeutic and diagnostic applications.Antibodies are the most prolific biologics in clinical environments because of their ability to bind targets with high affinity and specificity. However, antibodies also carry liabilities. They are often unstable and require costly cold-chain management to reach their destinations in active form. Because of their fragility, antibodies typically cannot be used in extreme environments like the gastrointestinal tract and can require lengthy infusions to administer to patients.
Oncurie develops targeted radionuclide therapy to create a cure for metastatic cancer through the use of novel molecular radionuclide technology, enabling healthcare providers to cure their patients. They are creating the technology to deliver radionuclides selectively to metastatic tissues.
MBF Therapeutics, Inc. is a veterinary oncology company that specializes in developing and commercializing innovative therapies for cancer treatment in dogs and cats. The company's product portfolio features targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing healthy tissues. Key products include MBFT-101, a combination therapy for sarcomas and lymphoma that utilizes a proprietary polyamine transport inhibitor alongside a potent inhibitor of ornithine decarboxylase, and MBFT-102, an immunotherapy based on the tumor suppressor/cytokine mda-7/IL24, which has shown promise in human clinical trials for various advanced cancers. Additionally, MBF Therapeutics is advancing a gene-based vaccine platform aimed at improving treatments for both cancer and infectious diseases in animals, with the potential to transform veterinary medicine. The company is located in Ambler, Pennsylvania, and maintains a strategic partnership with the Lankenau Institute for Medical Research.
Synvivia, Inc. is a biotechnology company founded in 2016 and based in Berkeley, California. It specializes in developing synthetic biology products, particularly ON-OFF switches for genetically engineered organisms. These protein switches can be controlled by small molecules, allowing for precise manipulation of biological functions. By integrating these switches into organisms, Synvivia aims to create engineered life forms that can be effectively used in healthcare. The company also focuses on generating biosensors that enhance enzymatic activities, facilitating easier disease diagnosis and enabling healthcare providers to deliver appropriate treatments.
Spekciton Biosciences provides biophotonic measurement systems and services, such as the rapid and precise early detection of plant stress and viability, as well as biosensors to detect fast soil and water contamination.
BioSapien is a pre-clinical biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications with reduced systemic side effects. The applications for this technology are currently under investigation for pancreatic cancer and lung cancer. The intended pipeline of indications is expected to expand into other cancers such as colorectal, breast, and stomach cancers. BioSapien's 3D-printed MediChip delivers FDA-approved toxic high-dose systemic therapies in a localized slow-release biodegradable mesh which is able to target tissues while improving patients' quality of care and life.
Aracari Biosciences specializes in developing advanced 3D Vascularized Micro-Organ platforms aimed at improving the drug discovery process. These platforms enhance the biological authenticity of pre-clinical testing by allowing for real-time imaging of vessel morphology, which facilitates the investigation of lead compound efficacy against tumors in a three-dimensional environment. The technology is designed to adapt to various physiological conditions and can be perfused with fluorophore-tagged dextrans of different molecular weights. This capability assists pharmaceutical companies in making informed decisions and accelerates the development of new drugs.
Medecipher is a highly innovative early-stage company providing decision-support solutions to help hospitals improve clinical operations. Medecipher’s suite of EMR-integrated real-time decision support tools leverages predictive analytics to proactively optimize clinical operations and drive meaningful improvements in patient care, nurse retention, and a hospital’s bottom line.
Green Sun Medical, LLC is a medical device company based in Fort Collins, Colorado, specializing in the design, development, and manufacturing of orthotic braces for treating Adolescent Idiopathic Scoliosis (AIS) and Kyphosis. Founded in 2013, the company focuses on creating a dynamic spinal alignment brace that applies continuous corrective pressure to the spine, assisting in the management of spinal deformities. This innovative brace not only promotes effective treatment but also enables physicians to monitor its performance remotely in real-time, thereby enhancing patient care and recovery outcomes. Green Sun Medical is dedicated to advancing spinal health through its technology-driven solutions.
Felix Biotechnology is working to accelerate the deployment of novel biotherapeutics to manage infectious diseases. Felix Biotechnology's bio-therapeutics targets antibiotic-resistant bacteria to manage infectious diseases precisely and effectively, allowing healthcare professionals to manage urgent microbial challenges in human health.
Biochip Labs provides blood disorder testing for conditions like sickle cell disease and thalassemia. The company was founded in 2019 and is headquartered in Cleveland, Ohio.
xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.
Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.
Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.
Zeteo is a defense and space company that specializes in prototype and transition innovative solutions. The company retains a wide network of affiliates with research, development, and production capabilities enabling idea generation, prototyping, and deployment. Zeteo was founded in 2013 and headquartered in Maryland, United States.
Tethys Research focuses on discovering high-value enzymes and chemical entities by applying its expertise across various disciplines to address challenges unsuitable for high-throughput screening methods. The company operates as a discovery entity, creating innovative technologies and collaborating with organizations that manufacture and market chemical products and processes. Through its contract and partnership initiatives, Tethys Research aims to enhance the capabilities of businesses in the chemical industry by providing tailored solutions that meet specific needs.
Frontier Bio Corporation, based in Oakland, California, develops and manufactures advanced bioprinting technologies to create lab-grown human tissues. Established in 2018, the company offers the FLUX-1, a 3D bioprinter that integrates conventional bioprinting methods with electro-hydrodynamic printing capabilities. This technology enables the production of complex tissues, such as skin, cartilage, and bone, while also facilitating drug toxicity testing, tissue implants, drug screening, and disease modeling. Frontier Bio aims to replace animal studies with ethically developed human tissues, ultimately working towards eliminating the organ transplant waitlist and improving patient outcomes. The company focuses on achieving complete cell survivability during the printing process, ensuring the viability of the printed tissues for various medical applications.
Kodikaz goal is to move from incremental cancer therapies with devastating side effects to durable cures through targeted therapies that can eradicate cancers. Zip-Code™ Technology platform is a first-in-class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ is derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.
Compact Medical is a developer of a medical bag-valve-mask (BVM) used to assist patients with emergency breathing issues. It specializes in the development of an ultra-compact breathing device which enhances resuscitation by preventing hyperventilation, providing medical personnel with a product to safely ventilate patients that are not breathing properly. It was founded in 2016 and is headquartered in Indianapolis, Indiana.
Biko Biolabs is a research company focused on the intersection of plastic waste and regenerative agriculture. The company was founded in 2020 and is based in Somerville, Massachusetts.
TheraCea Pharma is a biotechnology company based in Tucson that focuses on developing precision medicine for individuals with neurological disorders. As a spin-off from the University of Arizona, the company has developed and licensed advanced radiochemistry technology that enables efficient and rapid fluorine-18 radiolabeling of biomolecules. This innovative approach supports both clinical and research applications, particularly in the context of neurological conditions. TheraCea Pharma's treatments aim to counteract dyskinesia, a side effect commonly associated with L-dopa, the standard treatment for Parkinson's disease. By providing new diagnostic agents, the company enhances medical professionals' capabilities in detecting not only neurological disorders but also cancer, thereby contributing to improved healthcare outcomes.
ZelosDx specializes in the development of blood testing products aimed at advancing research in brain health and diseases. The company provides researchers with access to proprietary technology that can be licensed and adapted for blood testing kits and automated laboratory equipment. Additionally, it offers pharmaceutical collaborators biomarker technology to support drug discovery efforts. By delivering critical data for diagnosis, monitoring, and evaluating therapeutic responses, ZelosDx facilitates significant advancements in the understanding and treatment of brain-related conditions.
Millions of people suffer from Sickle Cell Disease and other hemolytic anemias. KovaDx is making healthcare accessible to these individuals by providing an affordable and easy to use point-of-care solution. Our system is based on Quantitative Phase Imaging and uses deep learning to make predictions.
Nano PharmaSolutions specializes in enhancing the bioavailability of insoluble drugs through its proprietary nanoformulation technology. The company has developed an innovative phase-transition technology platform that significantly improves the solubility of BCS 2 and BCS 4 active pharmaceutical ingredients (APIs) without the need for excipients, which are typically used in traditional processes like spray-dry dispersion and emulsification. By vaporizing the API and depositing it onto a carrier molecule, Nano PharmaSolutions enables the production of nanoparticles that can be processed into various dosage forms. Additionally, the company focuses on delivering neurodegenerative therapeutics directly to the brain via an intranasal route, facilitating a rapid onset of action and enhancing safety profiles. Their pipeline includes treatments for conditions such as Parkinson's disease, peripheral neuropathy, and substance abuse disorders, positioning Nano PharmaSolutions as a key player in the field of nanomedicine.
Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.
COPD will cost $61 billion per year by 2029, but no technologies can evaluate lung function from home, leaving patients and doctors to rely on questionnaires. Samay will disrupt the remote diagnostic market just as Dexcom did with Diabetes and iRhythm with cardiac arrhythmias. Our chest patches use a patented technology that diagnoses COPD with 90% accuracy and detects exacerbation biomarkers with 83% accuracy, passively. We're building an AI-assisted management and diagnostic platform to accompany patients and doctors throughout the care continuum, from exacerbation detection to determining effective therapies for more personalized care, all from home.
MedChem Partners is a medicinal chemistry CRO that specializes in developing small molecule therapeutics. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Hermes Life Sciences develops solutions to improve the accuracy and accessibility of blood testing at the point of care. The company was founded by Sasank Vemulapati.
Sequitur Health develops medical devices with the aim of saving, extending, and improving people's lives. The company was founded in 2019 and is headquartered in Scottsdale, Arizona.
BioSens8 is a developer of advanced biosensors designed to enhance health monitoring and prevent chronic diseases. The company's innovative platform offers real-time, quantitative biosensors that serve various applications. In healthcare, these biosensors assist women in assessing their fertility health, providing crucial information for family planning. In agriculture, BioSens8's technology enables farmers to manage herds effectively and optimize animal reproduction. Additionally, the biosensors can evaluate environmental health, contributing to the revitalization of fragile ecosystems. By catering to the healthcare, agriculture, military, and biomanufacturing sectors, BioSens8 aims to provide efficient solutions for holistic health monitoring.
HC Simulation specializes in products that use the HumMod engine to provide a high-quality simulation of human physiology. The company was founded in 2011 and is headquartered in Canton, Mississippi.
Theromics is the developer of a tool to address the unmet medical need to create more effective ablation zones during image-guided thermal ablation of soft tissue. Their HeatSYNC TA is used during microwave and radiofrequency ablations of cancerous tumors. Their heatSYNCTM Gel is a novel biopolymer thermal accelerant that amplifies the movement of heat energy in soft tissue and bone. The gel is made from a naturally occurring protein and delivered via a syringe, laparoscope, or bronchoscope.
SingletO2 Therapeutics creates new treatments for periodontal disease using singlet oxygen. The company was founded in 2015 and is headquartered in New Providence, New Jersey.
Drive Therapeutics is a new biotechnology company that strives to improve treatment for retinal diseases.
NeuroTechR3 is a Biomedical Device/Digital Health start-up that develops affordable and versatile rehabilitation technologies for improving upper extremity function in individuals suffering from the effects of brain injury, such as stroke and cerebral palsy. Their innovation, R3THATM, makes personalized telerehabilitation possible by combining machine learning-driven cloud technology with exergames specifically designed to promote neuroplasticity integrating motion tracking, analytics and real-time biofeedback. NeuroTechR3 is dedicated to shifting the rehabilitation industry into a more proactive, patient-centered process by offering solutions for clinicians to balance the demand on efficiency with quality of care to improve patient recovery outcomes The company, founded 2020 by four women, is a spinout from New Jersey Institute of Technology Biomedical Engineering Department and Rutgers School of Health Professions. It currently has offices at VentureLink@NJIT in Newark, NJ, and at ic@3401 in Philadelphia, PA, and is well positioned in the local market through established relationships with rehabilitation hospitals, out-patient centers, and therapists. The core competence of the company is in using biomedical engineering and computer science to develop its technology. The founders/executive team draws from complementing skills with backgrounds in engineering, software development, digital design, and business development, which allows them to build a data driven, tech savvy, and innovative company with a clear focus on understanding exactly what is happening in our industry to be able to adapt quickly to create sustainable revenue streams. The company’s vision is to change the healthcare system for the better by becoming a disruptor in exergame rehabilitation, expanding this field by providing sustainable and accessible solutions for individuals with all types of impairments. By advancing rehabilitation devices and ML-driven technology, it will have a significant positive impact on people everywhere, contributing to the overall improvement of human health.
Paramita Therapeutics is a biotech company that focuses on developing new cancer and infectious disease therapeutics. The company was founded in 2018 and is headquartered in San Diego, California.
InSoma Bio integrates biology and materials science to solve problems in tissue engineering and regenerative medicine. It offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular tissues. The company also offers reconstructive plastic surgeries and injectable materials.
LiteraSeed operates a clinically validated digital health platform designed to enhance communication between healthcare providers and low health literate patient populations. The platform addresses significant challenges faced by public health providers, particularly in serving patients who may not speak English or have other communication barriers. By enabling these individuals to accurately and remotely self-report symptoms, LiteraSeed aims to prevent costly misdiagnoses, adverse events, and unnecessary emergency room admissions. This approach not only improves access to care for disadvantaged patients but also makes clinical encounters more productive, fostering better understanding of health status and overall patient outcomes.
EnVision Endoscopy offers remedies that assist policymakers, insurers, clinicians, and patients. The company created an image-guided suturing system for use with endoscopes to address these clinical needs because they have a track record of launching medical devices. The biodegradable, one-time-use item is attached to flexible endoscopes. This method makes procedures easier to complete while giving many gastroenterologists and surgeons access to them.
Avior Bio is a clinical-stage, pharmaceutical company developing drugs for distressed neurological conditions. Using its disruptive drug delivery technology – Speedit™ Transmucosal Film Technology – we are positioned to develop products that bring unsurpassed value in efficacy and safety. Avior has an excellent management team, a strong advisory board, supportive partners, dedicated scientists, and knowledgeable clinicians that position us to be successful.
Partillion Bioscience is an early-stage life science company developing a functional single-cell analysis platform to analyze and sort single cells based on secreted proteins. The platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological functions.
Gate Scientific makes products that enable great research and improve healthcare decisions by bringing to market intuitive solutions that simplify complex problems. By bringing to market intuitive solutions that simplify complex problems, they allow for the latest technologies to benefit more people.
InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.
Oculomotor Technologies offers a vision therapy tool for optometry practices to treat convergence insufficiency and other vergence disorders.
Precision Theranostics develops prognosis-based intervention strategies for the early detection and treatment of fatal diseases. The company was founded in 2019 and is headquartered in Baltimore, Maryland.
Allegro 3D is a Digital Light Processing printing industry. Allegro 3D DLP-based bioprinting technology enables high-precision and high-throughput manufacturing of biomedical devices and human tissues for cell culture, drug screening, and regenerative medicine applications.
CellDrop Biosciences develops hydrogel-based point-of-care diagnostics and targeted biomaterial delivery technology. The company was established in 2017 and is headquartered in Laramie, Wyoming.
RevMedica is a medical device manufacturer focused on enhancing surgical performance through its innovative laparoscopic surgical stapler. The company's products provide critical decision-making information, enabling surgeons to approach soft tissue management more effectively. By incorporating artificial intelligence guidance, RevMedica's systems extend the tactile reach of surgeons to target tissues, streamline workflows, and reduce costs. Additionally, the company emphasizes minimizing toxic waste disposal, positioning its offerings as both efficient and environmentally responsible. Overall, RevMedica aims to improve surgical outcomes by balancing advanced features with user-friendly design.
Grapevine Health is a data-driven health media company that delivers health information to underserved communities. The company leverages technical expertise, trusted messengers, and empathetic storytelling to democratize health information, empower patients, and sustain healthy behaviors.
HealthTrends.AI is a trusted third party delivering ongoing authoritative health information that is independently auditable. Our mission is to help organizations turn health data into actionable information. We offer a platform-agnostic solution embedded in our products. Products are available as streaming feeds, APIs, and dashboards enabling flexible integration with 3rd party tools (Power BI, Tableau, etc.). Our tools are designed to be easily accessible and plug into and enhance your existing in-house systems with an intuitive platform.
NeuroTechR3 is a Biomedical Device/Digital Health start-up that develops affordable and versatile rehabilitation technologies for improving upper extremity function in individuals suffering from the effects of brain injury, such as stroke and cerebral palsy. Their innovation, R3THATM, makes personalized telerehabilitation possible by combining machine learning-driven cloud technology with exergames specifically designed to promote neuroplasticity integrating motion tracking, analytics and real-time biofeedback. NeuroTechR3 is dedicated to shifting the rehabilitation industry into a more proactive, patient-centered process by offering solutions for clinicians to balance the demand on efficiency with quality of care to improve patient recovery outcomes The company, founded 2020 by four women, is a spinout from New Jersey Institute of Technology Biomedical Engineering Department and Rutgers School of Health Professions. It currently has offices at VentureLink@NJIT in Newark, NJ, and at ic@3401 in Philadelphia, PA, and is well positioned in the local market through established relationships with rehabilitation hospitals, out-patient centers, and therapists. The core competence of the company is in using biomedical engineering and computer science to develop its technology. The founders/executive team draws from complementing skills with backgrounds in engineering, software development, digital design, and business development, which allows them to build a data driven, tech savvy, and innovative company with a clear focus on understanding exactly what is happening in our industry to be able to adapt quickly to create sustainable revenue streams. The company’s vision is to change the healthcare system for the better by becoming a disruptor in exergame rehabilitation, expanding this field by providing sustainable and accessible solutions for individuals with all types of impairments. By advancing rehabilitation devices and ML-driven technology, it will have a significant positive impact on people everywhere, contributing to the overall improvement of human health.
Oculogenex is a biopharmaceutical company that specializes in gene therapy for the treatment of retinal disorders. The company was founded in 2020 and is headquartered in La Habra, California.
Kepley BioSystems offers ocean restorative technology to help stem the continued depletion of wild fish.
Enable Therapeutics
Grant in 2021
Enable Therapeutics is a biotechnology company developing a patented drug delivery platform. The company was founded in 2020 and is headquartered in Hopedale, Massachusetts.
Ortuvo is a company that specializes in developing research tools for 3D printing technology, specifically aimed at tissue engineering and the creation of custom bio-inks. Founded in 2020 and based in Baltimore, Maryland, Ortuvo serves the healthcare and biotech industries by providing innovative solutions that enhance the capabilities of 3D printing in medical applications.
Ansa Biotechnologies is manufactured via a chemical method that has remained essentially unchanged for 35 years and has approached a plateau. Ansa Biotechnologies is developing a novel DNA synthesis technology based on enzymes that will be more fast, accurate, and clean than existing methods. The technique promises to dramatically accelerate innovation in biological research and engineering.
Produces kits for protein sample preparation to enable better drug and biomarker discovery. vision is to be the leader of protein sample preparation, enabling the discovery of important therapeutics and diagnostics and bringing them to market faster than ever before.
Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
NeyroblastGX is a biotechnology company develops theranostic products to treat neurodegenerative and infectious diseases. The company was founded in 2020 and is headquartered in Murrieta, California.
- Next-Gen Fermentors For Next-Gen Business Needs - New Horizon Biotechnologies (NHB) is currently concluding testing of its patented Single Use Horizontal Fermentor system (SUHF™). These studies demonstrate the effectiveness of the system for single-use microbial fermentation and compares and contrasts it with legacy designs currently in use. Microbial fermentation is the basis for the production of a wide range of high value biopharmaceutical products, including antibiotics, vaccines, and therapeutic proteins. NHB intends to deliver production and operational cost savings and efficiencies with its new SUHF™ system that will fundamentally improve the global competitive edge of its users.
Cobio Diagnostics is a biotechnology company based in Golden, Colorado, founded in 2016. The company specializes in developing diagnostics aimed at rapid bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology can identify specific bacterial species and determine the most effective antibiotic treatment in under five hours. This innovative approach provides a faster and more targeted alternative to traditional diagnostic methods, allowing healthcare providers to make quicker and more informed decisions regarding antibiotic treatment for patients with bacterial infections.
BondTrue LLC, a medical device company, announces the receipt of a Phase II Maryland Industrial Partnerships (MIPS) award from the Maryland Technology Enterprise Institute, a unit of the A. James Clark School of Engineering at the University of Maryland. The joint grant, worth $100,000, will be used for continuing development and research on the company’s patented device (#9,408,672), which aims to automate the process of surgical incisions and closures. The MIPS program supports the development and commercialization of products and processes in Maryland through industry/university research partnerships. MIPS provides funds, matched by participating companies, to fund the research. After successfully completing Phase I, BondTrue plans to refine developed prototype designs, which will be used in research and testing.
Over 7 million Americans need biopsy procedures every year, costing over $8 billion; 20% of procedures fail to render an accurate diagnosis. Over 1 million patients have to go through costly, painful repeat biopsy procedures. Instapath makes digital microscopic imaging devices that improve rapid on-site evaluation (ROSE) of biopsies, reducing the need for repeat procedures and increasing operating room capacity and hospital revenue.
CytoRecovery manufactures microfluidic technology intended to recover biological cells from samples. It brings to market microfluidic technology to enable cell biologists and other life science researchers to rapidly select and recover rare, homogeneous, viable cell subpopulations from tissue, blood, and other biological samples. The company was founded in 2017 and is headquartered in Blacksburg, VA.
VeriSIM Life, Inc. is a biotechnology company based in San Francisco, California, that specializes in developing disease-specific biosimulation models to enhance drug development processes. Founded in 2017, the company utilizes its proprietary BIOiSIM platform to predict the clinical outcomes of new drugs prior to clinical trials, thereby replacing traditional animal testing methods. By employing artificial intelligence, VeriSIM Life aims to improve the accuracy and efficiency of drug development, ultimately contributing to personalized healthcare solutions. Their offerings are tailored to meet the needs of both pre-clinical and clinical programs, focusing on small molecules, large molecules, and viruses to facilitate better treatment options and increase human life expectancy.
Spatio Metrics offers a design analytics platform aimed at enhancing health outcomes through improved architectural design in healthcare facilities. By analyzing floor plans, the platform identifies design gaps and suggests performance improvements, enabling hospital administrators to make informed design investments. It bridges the divide between design, data, and human performance by leveraging computational analysis of spatial characteristics and trends. This approach integrates previously disconnected data sources, fostering collaboration among teams and allowing clients to test ideas and prioritize interventions. Ultimately, Spatio Metrics seeks to increase operational efficiency and enhance patient well-being by quantifying the effects of design on health outcomes.
FibrosIX is a biotechnology company develops drugs to prevent lung fibrosis in cancer patients. The company was founded in 2016 and is headquartered in East Lansing, Michigan.
Oncospace, Inc. is a medical technology company founded in 2018 and based in Baltimore, Maryland, specializing in personalized medicine for radiation oncology. It has developed an AI-powered platform that leverages clinical treatment data to create optimized treatment plans tailored to individual patients. This platform aims to enhance patient outcomes by minimizing side effects and improving the overall quality of life. Through the use of machine learning, Oncospace's technology establishes best-practice dosimetric goals, facilitating better planning and evaluation in radiation therapy. The company focuses on fostering collaborative relationships within the medical community, thereby advancing the field of radiation oncology.
Gradient Medical, founded in 2020 and based in Raleigh, North Carolina, specializes in developing innovative interventional oncology services, specifically focused on ACE therapy. This therapy utilizes electrical pulses designed to target cancer cells and disrupt essential biological functions. By incorporating real-time sensing technology, Gradient Medical provides clinicians with enhanced control over the treatment area, which optimizes therapeutic effectiveness and reduces treatment durations. This approach enables healthcare professionals to effectively treat large, inoperable tumors located near vital structures, addressing a critical need in cancer care.
Sperry Bio is focused on developing innovative medical devices, particularly the sperry micro-coring system, aimed at treating burns and enhancing wound healing while minimizing scarring. The company is engaged in research programs aligned with the objectives of the army medical research and materiel command, specifically within the clinical and rehabilitative medicine research domain. By creating advanced skin graft harvesting technologies, Sperry Bio seeks to alleviate the pain and limitations associated with existing treatment methods, addressing functional impairments caused by severe scarring and contraction. Their approach aims to improve both the effectiveness of burn injury treatments and the cosmetic outcomes for patients.
Kepler Diagnostics is a healthcare technology company that supplies specimen collection devices.
AthemBio is a biotechnology company focused on addressing significant challenges in biologics manufacturing through innovative technologies. The company specializes in developing advanced medical devices and bioprocessing systems designed to isolate and purify therapeutic antibodies. These solutions aim to enhance the treatment of COVID-19 and other infectious diseases, ultimately contributing to the fight against pandemics and emerging pathogens. AthemBio's commitment to creating effective bioprocessing solutions positions it as a key player in the healthcare sector.
CasTag Biosciences specializes in cell biology and regenerative medicine, focusing on revolutionizing the speed of endogenously protein analysis. The company aims to accelerate scientific discovery by offering tools that allow scientists to study novel genes in any experimental model.
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.
Grit Bio is a biotechnology company founded in 2017 and based in New York, NY, focused on developing cancer therapeutics specifically aimed at pharyngeal squamous cell carcinoma. The company's innovative approach targets the increased turnover of lipid metabolism and the production of oncogenic products associated with sphingolipid metabolism. By addressing these mechanisms, Grit Bio aims to enhance the safety of cancer treatment and extend remission periods for patients.
iReprogram is a cell regeneration lab that aims to expedite the delivery of next-generation personalized medicine. The company was founded in 2017 and is headquartered in Ann Arbor, Michigan.
O2M Technologies develops oxygen imaging devices for effective cancer and regenerative medicine treatments. The company was founded in 2017 and is headquartered in Chicago, Illinois.
GMJ Technologies develops microanalytical technologies for biopharmaceutical and biomedical applications. The company was founded in 2018 and is headquartered in Seattle, Washington.
BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies. The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft. During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast. The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase.
Vaxess Technologies is developing the MIMIX™ sustained release patch technology, the easiest and most effective way to administer vaccines and therapeutics. For vaccines, the controlled release simulates the pace of a natural infection, helping the body produce a slow, strong, and enduring ramp-up of immune response, ultimately boosting a vaccine’s effectiveness. Engineered for stability, Vaxess’s patch does not require refrigeration and can be shipped to and applied in low resource settings.
BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.
Ernest Pharmaceuticals is a biotechnology company that develops cancer-killing bacteria. The company was founded in 2016 and is headquartered in Hadley, Massachusetts.
Creative BioTherapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and viral diseases. The company aims to transform cancer and viral disease research by targeting the fundamental issues of immune evasion and drug resistance. With a focus on recurrent and drug-resistant cancers, Creative BioTherapeutics is creating first-in-class biologics designed to address critical needs in treatment, particularly for patients with recurrent metastatic breast cancer. This approach not only seeks to enhance tumor regression but also holds the potential for cures in both adult and childhood cancers, thereby improving treatment options for patients facing these challenging conditions.